BioNexus Gene Lab Corp. (BGLC) Gross Margin
- Gross margin · 12 months: Value 12.34%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 12.34% | Gross profit / revenue. Period ending 2026-06-30. $385.89K ÷ $3.13M × 100 ≈ 12.34% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 385.89K USD | Gross Profit |
| Revenue | 3.13M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $385.89K | $3.13M | (m) | 12.34% |
| 2026-03-31 | $740.93K | $5.31M | (m) | 13.95% |
| 2025-12-31 | $1.09M | $7.42M | (m) | 14.62% |
| 2025-09-30 | $1.40M | $9.47M | (m) | 14.77% |
| 2025-06-30 | $1.35M | $9.55M | (m) | 14.11% |
| 2025-03-31 | $1.27M | $9.27M | (m) | 13.68% |
| 2024-12-31 | $1.29M | $9.51M | (m) | 13.56% |
| 2024-09-30 | $1.25M | $9.26M | (m) | 13.47% |
| 2024-06-30 | $1.27M | $9.18M | (m) | 13.88% |
| 2024-03-31 | $1.33M | $9.78M | (m) | 13.56% |
| 2023-12-31 | $1.33M | $9.77M | (m) | 13.61% |
| 2023-09-30 | $1.40M | $10.34M | (m) | 13.56% |
| 2023-06-30 | $1.35M | $10.36M | (m) | 13.01% |
| 2023-03-31 | $1.27M | $10.28M | (m) | 12.37% |
| 2022-12-31 | $1.26M | $10.93M | (m) | 11.52% |
| 2022-09-30 | $1.32M | $11.33M | (m) | 11.68% |
| 2022-06-30 | $1.72M | $12.34M | (m) | 13.95% |
| 2022-03-31 | $1.94M | $12.94M | (m) | 15.03% |
| 2021-12-31 | $2.19M | $13.36M | (m) | 16.42% |
| 2021-09-30 | $2.12M | $14.24M | (m) | 14.89% |
| 2021-06-30 | $1.96M | $13.76M | (m) | 14.21% |
| 2021-03-31 | $1.65M | $11.77M | (m) | 13.99% |
| 2020-12-31 | $1.72M | $11.39M | (m) | 15.10% |
| 2020-09-30 | $18.77K | $83.06K | (m) | 22.60% |
| 2020-06-30 | $18.23K | $83.76K | (m) | 21.76% |
| 2020-03-31 | $33.63K | (m) | (m) | (m) |
| 2019-12-31 | $55.89K | $126.95K | (m) | 44.02% |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | $28.77K | $212.33K | (m) | 13.55% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |